A Real-World Study of Ipilimumab Treatment After Nivolumab Treatment in Melanoma in Japan

Bristol-Myers Squibb (BMS)

Status: Completed

Conditions: Melanoma

Treatments: Other: Non-Interventional

Study type: Observational

Funder types: Industry

Identifiers

NCT03165422

CA209-9DA

Details and patient eligibility

About

This is a medical chart review of ipilimumab treatment after nivolumab treatment in melanoma in Japan

Enrollment: 68 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult patients > 18 years of age or older
• Diagnosis of advanced melanoma (unresectable/metastatic), alive or deceased as of date of data collection
• Treated with ipilimumab between 31-Aug-2015 and 31-Mar-2017 before or after nivolumab treatment

Exclusion criteria

• Patients enrolled in any clinical trials at any time
• Overlapping use of nivolumab and ipilimumab

Trial design

68 participants in 1 patient group

Adult patients with melanoma

Description:

Adult patients with melanoma at participating centers in Japan

Treatment:

Other: Non-Interventional